Antithrombogenic elastomers: novel anticoagulant/complement inhibitor-controlled release systems.
We have introduced novel synthetic anticoagulant and complement inhibitors for controlled release systems with high biocompatibility. These drugs were molecularly designed for extremely high biospecific inhibition, are readily soluble in polar organic solvents, such that they have versatile applications in commonly used hydrophilic polymeric systems via an easily attainable one-step co-casting technique at a given amount of loading. Another characteristic feature of the controlled release system is that both release rate and duration are controlled by the material, formulation and fabrication variables. These are easily manipulated by the hydrophilicity of polymers, amount of loading and film thickness. The drug-impregnated system may generate a new dimension in the formulation of controlled release biocompatibility.
D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage*; D001120:Arginine / Q000031:analogs & derivatives; D001550:Benzamidines; D001672:Biocompatible Materials; D003692:Delayed-Action Preparations; D006146:Guanidines / Q000008:administration & dosage*; D010875:Pipecolic Acids / Q000008:administration & dosage*; D011140:Polyurethanes; D012408:Rubber; D013449:Sulfonamides; D013917:Thrombin / Q000037:antagonists & inhibitors
D000925:Anticoagulants; D001550:Benzamidines; D001672:Biocompatible Materials; D003692:Delayed-Action Preparations; D006146:Guanidines; D010875:Pipecolic Acids; D011140:Polyurethanes; D013449:Sulfonamides; D012408:Rubber; D001120:Arginine; D013917:Thrombin; C031942:argatroban; C032855:nafamostat